Brief: Following Positive Phase 2A Pancreatic Cancer Data, Can-Fite Advances Namodenoson Into Phase 2B Combination Study With Immunotherapy
13/05/2026 12:01
Can Fite Biopharma Ltd CANF.TA: FOLLOWING POSITIVE PHASE 2A PANCREATIC CANCER DATA, CAN-FITE ADVANCES NAMODENOSON INTO PHASE 2B COMBINATION STUDY WITH IMMUNOTHERAPY CAN FITE BIOPHARMA LTD - TO ADVANCE NAMODENOSON INTO PHASE 2B PANCREATIC CANCER STUDY WITH IMMUNOTHERAPY Source text: ID:nGNXbvHWkg Further company coverage: CANF.TA
Recent news on Can Fite Biopharma
See all newsBrief: Following Positive Phase 2A Pancreatic Cancer Data, Can-Fite Advances Namodenoson Into Phase 2B Combination Study With Immunotherapy
Can-Fite Biopharma surges as pancreatic cancer drug meets main goal in study
Brief: Can-Fite Completes Patient Enrollment In Phase 2A Pancreatic Cancer Study Of Namodenoson
Board Approved A 1-For-3,000 Reverse Split Of Company's Ordinary Shares
Brief: Can-Fite Provides Update On Clinical And Financial Status